Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Jose Trigo"'
Autor:
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R. Donald Harvey, Anthony J. Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C. Gregory, Harry Miao, Shining Wang
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Mivavotinib (TAK‐659/CB‐659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti‐PD‐1 therapy in cancer models. This dose‐escalation/expansion study inv
Externí odkaz:
https://doaj.org/article/543c6b5130f7472f8fd3b9ea9ea6f7e2
Autor:
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J. Perualila, Claudio A. Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
Publikováno v:
Advances in Therapy. 40:1187-1203
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Victor Moreno, Desamparados Roda, Joanna Pikiel, Jose Trigo, Joaquim Bosch-Barrera, Yvette Drew, Rebecca Kristeleit, Sandrine Hiret, David L. Bajor, Patricia Cruz, J. Thaddeus Beck, Srimoyee Ghosh, Christine Dabrowski, Grace Antony, Tao Duan, Jennifer Veneris, Eleftherios Zografos, Janakiraman Subramanian
Publikováno v:
Clinical lung cancer. 23(7)
Dostarlimab is an anti-programmed cell death protein-1 antibody being evaluated in recurrent/advanced solid tumors, including non-small cell lung cancer (NSCLC), in the ongoing Phase I, multi-center, open-label, 2-part (dose escalation and cohort exp
Autor:
Sophie, Cousin, Jean-Yves, Blay, Irene Braña, Garcia, Johann S, de Bono, Christophe, Le Tourneau, Victor, Moreno, Jose, Trigo, Christine L, Hann, Arun A, Azad, Seock-Ah, Im, Philippe A, Cassier, Christopher A, French, Antoine, Italiano, Vicki L, Keedy, Ruth, Plummer, Marie-Paule, Sablin, Matthew L, Hemming, Geraldine, Ferron-Brady, Anastasia, Wyce, Ahmed, Khaled, Antara, Datta, Shawn W, Foley, Michael T, McCabe, Yuehui, Wu, Thierry, Horner, Brandon E, Kremer, Arindam, Dhar, Peter J, O'Dwyer, Geoffrey I, Shapiro, Sarina A, Piha-Paul
Publikováno v:
International journal of cancerREFERENCES. 150(6)
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the reco
Publikováno v:
Liinc em Revista. 18:e5922
A desinformação causada pelo modelo de desenvolvimento predatório, ambientalmente e socialmente injusto torna-se o cenário para uma reflexão crítica voltada a uma maior conscientização ambiental e urgente mudança de paradigmas. Considerando
Autor:
Ruth, Plummer, Charlotte, Rees, Andrew, Hughes, Philip, Beale, Martin, Highley, Jose, Trigo, Sathyarathnarn, Gokul, Ian, Judson, Hilary, Calvert, Ann, Jackman, Fraser, Mitchell, Robert, Smith, Edwin, Douglass
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(4)
ZD9331 is a novel, direct-acting antifolate cytotoxic that does not require polyglutamation for activity, and is a specific thymidylate synthase inhibitor. This Phase I trial aimed to determine the maximum tolerated dose of ZD9331, given as a 30-min
Autor:
Carlos Pires, Katrien Torfs, Alain Areal, Charles Goldenbeld, Ward Vanlaar, Marie-Axelle Granié, Yvonne Achermann Stürmer, Davide Shingo Usami, Susanne Kaiser, Dagmara Jankowska-Karpa, Dimitrios Nikolaou, Hardy Holte, Toru Kakinuma, José Trigoso, Wouter Van den Berghe, Uta Meesmann
Publikováno v:
IATSS Research, Vol 44, Iss 3, Pp 166-179 (2020)
The road safety performance of a country and the success of policy measures can be measured and monitored in different ways. In addition to the traditional road safety indicators based on the number of fatalities or injured people in road traffic cra
Externí odkaz:
https://doaj.org/article/b2b4095cad9b4ec89535cae0e1fdcb52
Autor:
Andrés Cervantes, Victor Moreno, Maria Jure-Kunkel, Suresh Ramalingam, Emiliano Calvo, Patricia LoRusso, Brandon Higgs, Suzana Couto, Nora Pencheva, Santiago Ponce Aix, Daniel Cho, Alexander Muik, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Elena Garralda, Ulf Forssmann, Eleni Lagkadinou, José Trigo Pérez, Muhammad Furqan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/360983e5b17a4e2ba0207acb0fe600ea
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.